Volume 6, Issue 2, Pages (February 1997)

Slides:



Advertisements
Similar presentations
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells by Susanne M. Schmidt,
Advertisements

The T Cell Surface—How Well Do We Know It?
Nonsense Mutations Inhibit RNA Splicing in a Cell-Free System: Recognition of Mutant Codon Is Independent of Protein Synthesis  Said Aoufouchi, José Yélamos,
Volume 9, Issue 5, Pages (November 1998)
A Novel Cofactor for p300 that Regulates the p53 Response
Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma  Zhongyun Dong, Rakesh Kumar, Xiulan Yang,
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas by Jinsheng Weng, Seema Rawal, Fuliang Chu, Hyun Jun Park, Rakesh Sharma,
Potential Role of a Mismatched HLA-Specific CTL Clone Developed Pre-Transplant in Graft Rejection following Cord Blood Transplantation  Hiroto Narimatsu,
Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role.
CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib–associated renal carcinoma antigens with ubiquitous or restricted.
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA by Caterina Milazzo, Volker L. Reichardt, Martin.
Levels of Polyadenylation Factor CstF-64 Control IgM Heavy Chain mRNA Accumulation and Other Events Associated with B Cell Differentiation  Yoshio Takagaki,
Volume 7, Issue 6, Pages (December 1997)
Volume 15, Issue 4, Pages (October 2001)
Volume 130, Issue 2, Pages (February 2006)
Human Leukocyte Antigen–DO Regulates Surface Presentation of Human Leukocyte Antigen Class II–Restricted Antigens on B Cell Malignancies  Anita N. Kremer,
Volume 6, Issue 2, Pages (February 1997)
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Xenoinfection of nonhuman primates by feline immunodeficiency virus
Volume 8, Issue 5, Pages (May 1998)
Biochemical Mechanisms of IL-2–Regulated Fas-Mediated T Cell Apoptosis
Volume 11, Issue 5, Pages (November 1999)
Durbaka V.R Prasad, Sabrina Richards, Xoi Muoi Mai, Chen Dong  Immunity 
Volume 6, Issue 2, Pages (February 1997)
Volume 13, Issue 3, Pages (September 2000)
Volume 5, Issue 2, Pages (August 1996)
Volume 10, Issue 2, Pages (February 1999)
Balthazar B Cazac, Jürgen Roes  Immunity 
Volume 19, Issue 2, Pages (August 2003)
The Pathway for Processing Leader-Derived Peptides that Regulate the Maturation and Expression of Qa-1b  Ailin Bai, James Broen, James Forman  Immunity 
Yongli Bai, Chun Yang, Kathrin Hu, Chris Elly, Yun-Cai Liu 
Volume 7, Issue 4, Pages (October 2016)
Jürgen Ruland, Gordon S Duncan, Andrew Wakeham, Tak W Mak  Immunity 
James I Kim, I-Cheng Ho, Michael J Grusby, Laurie H Glimcher  Immunity 
Volume 28, Issue 3, Pages (March 2008)
CD22 is a negative regulator of B-cell receptor signalling
Andrew J Henderson, Ruth I Connor, Kathryn L Calame  Immunity 
Volume 14, Issue 2, Pages (February 2001)
Volume 133, Issue 3, Pages (September 2007)
Volume 15, Issue 5, Pages (November 2001)
Volume 11, Issue 19, Pages (October 2001)
Soluble CD86 Is a Costimulatory Molecule for Human T Lymphocytes
Both E12 and E47 Allow Commitment to the B Cell Lineage
Volume 17, Issue 3, Pages (September 2002)
Volume 12, Issue 5, Pages (November 2005)
IgH Class Switch Recombination to IgG1 in DNA-PKcs-Deficient B Cells
Volume 10, Issue 3, Pages (September 2006)
The Binding Site of NK Receptors on HLA-C Molecules
B7h, a Novel Costimulatory Homolog of B7. 1 and B7
Volume 16, Issue 3, Pages (March 2002)
Volume 7, Issue 2, Pages (August 1997)
Volume 11, Issue 2, Pages (August 1999)
Volume 32, Issue 2, Pages (February 2010)
Volume 6, Issue 2, Pages (February 1997)
Potential Role of a Mismatched HLA-Specific CTL Clone Developed Pre-Transplant in Graft Rejection following Cord Blood Transplantation  Hiroto Narimatsu,
Volume 55, Issue 2, Pages (February 1999)
Volume 4, Issue 6, Pages (June 1996)
Negative Selection at the Pre-BCR Checkpoint Elicited by Human μ Heavy Chains with Unusual CDR3 Regions  Yoshiyuki Minegishi, Mary Ellen Conley  Immunity 
Volume 12, Issue 1, Pages (January 2000)
The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes  Robert H Vonderheide, William C.
Molecular Therapy - Oncolytics
Volume 8, Issue 2, Pages (February 1998)
Volume 4, Issue 4, Pages (October 1999)
Volume 9, Issue 2, Pages (August 1998)
Volume 4, Issue 2, Pages (February 1996)
Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands
Laurel L Lenz, Beverley Dere, Michael J Bevan  Immunity 
Volume 10, Issue 1, Pages (January 1999)
Volume 115, Issue 4, Pages (October 1998)
Differences that Matter
Presentation transcript:

Volume 6, Issue 2, Pages 199-208 (February 1997) Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor  Hideyuki Ikeda, Bernard Lethé, Frédéric Lehmann, Nicolas Van Baren, Jean-François Baurain, Charles De Smet, Hervé Chambost, Massimo Vitale, Alessandro Moretta, Thierry Boon, Pierre G Coulie  Immunity  Volume 6, Issue 2, Pages 199-208 (February 1997) DOI: 10.1016/S1074-7613(00)80426-4

Figure 1 Lytic Activity of CTL Clone 17 (A) Sensitivity of 51Cr-labeled target cells to lysis by anti-LB33-E CTL clone 17. LB33-MEL.B-1 (MEL.B) is a clonal subline of the melanoma cell line LB33-MEL.B derived from a metastasis resected from patient LB33 in 1993. These cells have lost expression of all HLA class I molecules except HLA-A24. LB33-EBV-B is an EBV-transformed B cell line from patient LB33. Anti-HLA-A24 monoclonal antibody C7709A2 was used to inhibit lysis of MEL.B cells by the CTL by adding a 1:45 dilution of ascitic fluid from mice inoculated with the hybridoma cells. (B) Inhibition of the lytic activity of CTL 17 by an anti-CD3 monoclonal antibody. Target cells and CTL were incubated over 2.5 hr in the absence or presence of anti-CD3 monoclonal antibody UCHT-1 (20 μg/ml) or isotype-matched anti–interleukin-2 receptor β antibody CF1, and chromium release was measured. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 2 Identification of a cDNA Clone Encoding the Antigen Recognized by CTL 17 (A) Stimulation of CTL 17 by COS-7 cells cotransfected with vector pcDNAI/Amp containing cDNA clone 5E10 and vector pcDNA3 containing the autologous HLA-A*2402 cDNA. Control stimulator cells included the MEL.B cells and COS-7 cells transfected with HLA-A24 alone. The concentration of TNF released in the medium was measured using the TNF-sensitive WEHI-164 c13 cells. (B) Lysis by CTL 17 of a clone obtained by transfecting HLA-A24 acute lymphocytic leukemia cell line LB804-ALL with expression vector pEF-PL3 containing the cDNA clone Hi2. Control target was the untransfected cell line LB804-ALL. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 3 Sequence of cDNA Hi2 and Sequence of the Protein Encoded by the Longest Open Reading Frame Primers OPC183, OPC184, OPC189, and OPC190 used for the analysis of PRAME expression by PCR are indicated by horizontal arrows. The polyadenylation signal is underlined. The LB33-E antigenic peptide is boxed. The sequence of cDNA 5E10 is delimited by the square brackets. It contains two NsiI sites, indicated with vertical arrows, which were used for the localization of the antigenic peptide. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 4 Northern Blot Analysis of the Expression of PRAME in Tumor Cell Lines and in Normal Tissues Lanes contained 2 μg of poly(A)+ RNA from tumor cell lines and from adult human tissues (Clontech). The three membranes were hybridized simultaneously with 32P-labeled cDNA Hi2, washed under stringent conditions, and autoradiographed over 10 days to detect a low level of expression in the normal tissues. Control hybridization was performed on the same membranes with a β-actin probe. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 5 Expression of the PRAME Gene Analyzed with RT–PCR on Normal Tissues Expression was tested by reverse transcription of total RNA and PCR amplification with primers OPC189 and OPC190 shown in Figure 3. The 561 bp product is not observed when genomic DNA is tested. A semi-quantitative measurement was obtained by combining a limiting number of PCR cycles, comparing the result with a standard curve of RNA from MEL.A cells, and making a correction for the integrity of the RNA by taking into account the expression level of the β-actin gene. Each point represents the level of PRAME expression found in a sample of normal tissue. The results are expressed relative to the level of expression of the PRAME gene measured in the MEL.A cells, which is equivalent to that measured in the MEL.B cells. The limit of detection is indicated with a broken line. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 6 Inhibition of the Lytic Activity of CTL 17 by HLA Class I Molecules Expressed on the Target Cells (A) Cytolytic activity of anti-PRAME CTL 17 on autologous melanoma cells MEL.A, a clonal subline of the melanoma cell line LB33-MEL.A derived from patient LB33 in 1988. These cells express HLA-A24, A28, B13, B44, Cw6, and Cw7. Anti-HLA-B or C monoclonal antibody B1.23.2 was added in the lysis assay as a 1:60 dilution of ascitic fluid from mice inoculated with the hybridoma cells. (B) Cytolytic activity of CTL 17 on MEL.A-1.1.1 cells. MEL.A-1.1.1 is a variant, derived from the MEL.A cells, selected in vitro for resistance to autologous CTL clones 159/3 and 159/5. It has lost the expression of a complete HLA haplotype: HLA-A28, B44, and Cw7. The MEL.A-1.1.1 cells were transfected with the autologous HLA-B*4402 or HLA-Cw*0704 alleles cloned into expression vectors, and clonal lines isolated from the transfected populations were tested for their sensitivity to lysis by CTL 17. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 7 Expression of Surface Antigens by CTL 17 Cells were incubated with the indicated murine monoclonal antibodies or without antibody, washed, labeled with goat anti–mouse immunoglobulin antibodies coupled to fluorescein, and analyzed by flow cytometry. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 8 Lytic Activity of CTL 17 against MEL.A Cells in the Presence of an Anti-p58.2 Antibody CTL 17 (10,000 cells per well) were incubated for 30 min at 4°C with the indicated concentrations of anti–p58.2 IgG1 monoclonal antibody GL183 (closed circles), anti–p58.1 IgG1 monoclonal antibody EB6 (open triangles), or anti–MHC class II IgG2a monoclonal antibody L243 (open circles). 51Cr-labeled MEL.A cells were then added (1000 cells per well) and chromium release was measured after 4 hr. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)

Figure 9 Lysis by CTL 17 of Autologous EBV-Transformed B Cells Incubated with the PRAME-Encoded Peptide LYVDSLFFL 51Cr-labeled EBV-transformed B cells from patient LB33 were incubated first for 30 min at 4°C with anti-HLA-B or C monoclonal antibody B1.23.2 (closed circles; 1:50 dilution of ascitic fluid from mice inoculated with the hybridoma cells) or without antibody (open circles) and then for 30 min at 20°C with the indicated concentrations of peptide. CTL 17 were then added at an E:T ratio of 10:1, and chromium release was measured after 4 hr. Immunity 1997 6, 199-208DOI: (10.1016/S1074-7613(00)80426-4)